Meltwind: Investment Portfolio & Startup News
Meltwind
To add a bio or update investment portfolio click update information.
Investment Portfolio


Qureight lands £15m Series B led by Molten Ventures to bring AI imaging to clinical trials for lung and heart disease
Qureight is an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials, with a focus on lung and heart disease. Deep learning models built on 3D chest imaging quantify structural changes that indicate disease progression, giving biopharma partners measurable endpoints during trials.


IMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
IMU Biosciences is a biotechnology company that uses a simple blood sample to measure over 100 million immune data points by combining high-fidelity multi-omic analysis with proprietary machine learning analytics. The platform is designed to enable disease diagnosis, monitor treatment progression, and predict treatment suitability for individual patients.


Enhanced Genomics raises £14m Series A from investors to advance therapeutics pipeline with its 3D multi-omics platform
Enhanced Genomics uses a three-dimensional multi-omics platform to identify genetically validated drug targets, supporting the development of new medicines for complex common diseases.
- 2(12 months)
- meltwind.co.uk
More venture news
- 17 Nov 2026

Model MLModel ML secures a £190m Series B led by General Atlantic and QED Investors to expand its AI operating system for financial services
Series BFintech - 16 Nov 2026

SubdialSubdial secures a £15m Series B led by Gresham House Ventures to buy and sell pre-owned watches
Series BConsumer - 12 Nov 2026

GriffinGriffin closes a £15m Series B led by Octagon Partners to add cards and stablecoin payments to its banking platform
Series BFintech